Board of Directors
Mr. Graves is a global industry leader with more than 20 years of U.S. and global general management experience in top-tier U.S. and Europe-based pharmaceutical and biotechnology companies, including Merck, Novartis, and Vertex. He has successfully built and managed several of the largest multibillion-dollar franchises in the industry and developed and launched 12 blockbuster brands in a broad range of general medicine, specialty, and orphan disease areas. In addition to driving dynamic top- and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early-stage companies: Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Mr. Graves is currently the Chairman, President, and CEO of Intarcia Therapeutics. Prior to that, he served as Executive Vice President, Head of Corporate and Strategic Development, and Chief Commercial Officer at Vertex Pharmaceuticals. Prior to his tenure at Vertex, Mr. Graves spent nearly 10 years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business Unit and Chief Marketing Officer for the Pharmaceuticals division. Prior to his tenure at Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck Pharmaceuticals, where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves is Chairman of the Board at Intarcia and at Radius Health and serves as a Director at Achillion and Pulmatrix. He holds a BS in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, the Wharton School, and the University of Michigan.
Mr. Auerbach is the Founder, President, and CEO of Puma Biotechnology, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Previously, he founded Cougar Biotechnology and served as the company's President and CEO until the company's acquisition by Johnson & Johnson in 2009. Following the acquisition, Mr. Auerbach served as the Co-Chairman of the Integration Steering Committee at Cougar that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate, for the treatment of advanced prostate cancer. Prior to founding Cougar, Mr. Auerbach was a Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific, and clinical due diligence as well as selection of biotechnology companies followed by the company. Prior to that, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, where he was responsible for research coverage of small-capitalization biotechnology companies. Previous to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach received a BS in Biomedical Engineering from Boston University and an MS in Biomedical Engineering from the University of Southern California.
Dr. Willard Dere is Executive Director of Personalized Health at the University of Utah Health Sciences Center, and a member of the Department of Medicine and Division of Endocrinology and Metabolism. Prior to re-joining academia, Dr. Dere was in the biopharmaceutical industry for 25 years. He started working at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. At Eli Lilly, he led the development of Evista and Forteo. He joined Amgen in 2003 where he held multiple roles including head of global development, international medical, and both corporate and international chief medical officer. At Amgen, he led the development program of Prolia and several other programs. Dr. Dere retired from Amgen at the end of October 2014.
Dr. Dere received a B.A. degree in Zoology and History and an M.D. degree from the University of California, Davis. He has published over 50 articles; wrote and co-edited a primary care textbook; was awarded the 2008 transformational leadership award from UC Davis; and is a fellow in the American College of Physicians.
Ansbert Gadicke, M.D., co-founded MPM in 1997 with his partner Luke Evnin. Over many years the MPM team they have led has been the inspiration and driving force behind building leading biopharmaceutical companies such as Biomarin, CoStim Pharmaceuticals, Epizyme, Pacira, and Pharmasset. MPM believes that these companies are some of the biggest successes in biotech history; companies that ultimately resulted in helping thousands of patients live longer and with vastly improved lives. Ansbert was the lead investor and has served on the boards of several of MPM’s most successful investments including BioMarin, Idenix, and Pharmasset.
Prior to co-founding MPM, Ansbert led MPM’s Advisory and Investment Banking business from 1992 to 1996, and from 1989 to 1992 he was at The Boston Consulting Group in their Boston office’s Health Care Group. Ansbert received an M.D. from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University, and published in leading scientific journals such as Nature and Cell. At the German Cancer Research Center, Ansbert cloned the first cDNAs of HPV16 and 18 while under the leadership of Professor Harald zur Hausen, who received the Nobel Prize in Physiology or Medicine in 2008.
Ansbert’s commitment to drug discovery and curing disease inspires his work and that of his team in building leading biotechnology companies at MPM, as well as his commitments outside of MPM. He is a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of Massachusetts General Hospital.
Mr. Hughes serves as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc. Prior to Intarcia, he served as a Director at Brookside Capital, a multi-billion dollar hedge fund under the Bain Capital umbrella, managing public and private healthcare investments. Owen has 16 years of investing experience on both the buy and sell side, including positions at Pyramis Global Advisors, Triathlon Fund Management, Ziff Brothers Investments and Morgan Stanley/Merrill Lynch. He earned a bachelor of arts from Dartmouth College, held All-Ivy Honors, Academic All-Ivy Honors and was a four-year letterman on the varsity ice hockey team.
Tony Rosenberg is retired from Novartis where he was Head of M&A and Licensing. Most recently he was responsible for the Portfolio Transformation transactions undertaken by Novartis, which are seen as landmark deals in the industry.
Tony joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basle, initially in international product management (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit. In 2005 he was appointed Global Head Business Development & Licensing (Pharma) and has managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestment and M&A deals. In 2010 he was given additional responsibility for leadership of the Molecular Diagnostics group. In 2013 he was appointed as Head M&A and Licensing (Corporate).
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
Robert (Bob) Ward is President and Chief Executive Officer of Radius. He is a global pharmaceutical industry leader managing all stages of drug development, commercialization, and strategic dealmaking and partnerships across multiple therapeutic areas. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca (AZ), where he led search and evaluate activities in areas outside of AZ’s historical therapeutic focus, including orphan drugs and endocrinology. In addition, he served as Co-Chair of the Joint Development Committees in AZ’s drug development partnerships with Alcon and Galderma. After starting his career in the Molecular Biology discovery group at Genentech, Mr. Ward progressed through a series of management and executive roles with established biopharmaceutical companies including NPS Pharmaceuticals, Schering-Plough (Merck), and Bristol-Myers Squibb. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara; an M.S. in Management from the New Jersey Institute of Technology; and an M.A. in Immunology from The Johns Hopkins University School of Medicine.
Debasish Roychowdhury is a medical oncologist with over 15 years of comprehensive pharmaceutical industry and senior management experience and over 14 years of patient care, academic research and teaching experience. Debasish is a leader in the pharmaceutical industry across multiple functional and cross-functional areas, regions and matrices, including – all stages of R&D, regulatory, commercial operations and medical affairs, market access, business development and alliance management. Debasish was involved in nine new drug approvals in US and EU and other markets and numerous supplemental approvals.
Debasish Roychowdhury is currently President of Nirvan Consultants, LLC and advises biotechnology companies and institutions. He was one of the founding members of the Seragon Clinical and Scientific Advisory Board and was the company’s Chief Medical Officer where he played a key role in the development and advancement of Seragon’s selective estrogen receptor degrader (SERD) platform for breast cancer and other hormone-driven cancers till the company was acquired by Roche in August 2014.
Prior to Seragon, Debasish was the Senior Vice President and Head of the Global Oncology Division at Sanofi till November 2013. Prior to that, he served as the Vice President for Clinical Development at GlaxoSmithKline and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. He is a member of the Board of Directors for Lytix Biopharma AS.
Catherine Friedman has served as an independent consultant serving public and private growth companies since 2006. Prior to that, Ms. Friedman held the position of Managing Director at Morgan Stanley from 1997 to 2006 and head of West Coast Healthcare and co-head of the Biotechnology Practice at Morgan Stanley from 1993 to 2006. She originally joined Morgan Stanley in 1982 and worked in its New York, London and Silicon Valley offices. Since 2007, Ms. Friedman has been a director of XenoPort Inc., where she serves on the Audit and Nominating and Governance Committees, Enteromedics, where she serves as Chair of the Audit Committee, and in 2014, she joined the Board of Theravance and serves on its Audit and Compensation Committees. Ms. Friedman joined the board of GSV Capital, a publicly traded investment fund, in 2013 and serves as Chair of the Audit Committee and member of the Valuation Committee. Ms. Friedman is a member of the Board of Trustees for Sacred Heart Schools in Atherton. She is a graduate of Harvard University and received an MBA from the University of Virginia Darden School of Business, where she is currently a Darden School Foundation Board of Trustees member .
Mr. Garnier is currently Chairman of the Board of Actelion Ltd., and was previously Chief Executive Officer of GlaxoSmithKline plc. In addition, Dr. Garnier is also a member of the Board of Directors of United Technologies Corporation and of Renault S.A., and an Operating Partner at Advent International. Dr. Garnier previously served as Chief Executive Officer of Pierre Fabre S.A. from 2008 to 2010 and as Chief Executive Officer and Executive Member of the Board of Directors of GlaxoSmithKline plc from 2000 to 2008. Dr. Garnier served as Chief Executive Officer of SmithKline Beecham plc in 2000 and as Chief Operating Officer and Executive Member of the Board of Directors of SmithKline Beecham plc from 1996 to 2000. In 2009, he was made a Knight Commander of the British Empire. In 2007, he was promoted from Chevalier to Officier de la Légion d’Honneur of France. In 2006, he was named to the global list of top 20 CEOs by the Best Practice Institute. Dr. Garnier was previously Chairman of Cerenis from 2010 to 2011, and a board member of the Stanford Advisory Council on Interdisciplinary Biosciences, Weill Cornell Medical College and the Dubai International Capital Advisory Board. He is a member of the Advisory Board of the Newman’s Own Foundation. Dr. Garnier is 68.